Abstract

Hot melt extrusion has gained considerable attention as a novel technique for taste masking of bitter APIs. The aim of this study was to investigate whether hot melt extrusion could be used to develop taste masked formulations of isoniazid and also to evaluate and correlate different taste assessment methods Two polymers with different physico-chemical properties, Soluplus and Eudragit E-PO were chosen as carriers for the drug. Eudragit E-PO has already been widely used for taste masking due to its selective release properties, while Soluplus has not been studied in this regard but provides a useful comparator of a polymer that should release the drug reasonably efficiently. Polymeric formulations of isoniazid were produced with drug loadings of 20% and 30% w/w. The solid state characteristics of the formulations were assessed by differential scanning calorimetry and powder X-ray diffraction. The taste of isoniazid was assessed using the rodent Brief Access Taste Aversion (BATA) model, while formulations were assessed using the electronic tongue and dissolution under simulated oral conditions. Investigation into the drug loading effect with these two polymers showed that all Soluplus based extrudates with drug loading up to 30% w/w were fully amorphous while Eudragit E-PO based extrudates contained crystalline drug as demonstrated by both DSC and PXRD, dependent on loading. BATA testing of isoniazid gave an IC50 value, i.e. the dose of drug which inhibits 50% of licks, of 11.1mg/mL. Taste assessment of the formulations using both simulated oral drug release and the electronic tongue demonstrated that Eudragit E-PO based formulations had a better taste masking efficiency than Soluplus. This is due to the fact that significantly less isoniazid is released from the Eudragit E-PO based formulations under oral conditions.

Highlights

  • A significant number of drugs currently on the market or under development have poor organoleptic properties which, unless formulated appropriately, can be very unpalatable

  • All Eudragit E-PO based formulations were processed at 130°C and 50rpm

  • hot melt extrusion (HME) was successfully used to produce polymeric formulations of isoniazid with drug loadings of up to 30%

Read more

Summary

Introduction

A significant number of drugs currently on the market or under development have poor organoleptic properties which, unless formulated appropriately, can be very unpalatable. In recent years hot melt extrusion (HME) has emerged as a novel processing method for taste masking of bitter drugs (Maniruzzaman et al, 2014). Hot melt extrusion is a solvent free process, avoiding the need for this step and making it an environmentally friendly process. It is a continuous process which is relatively simple to scale up (Maniruzzaman et al, 2014), and can be adapted to meet the goals of the FDA process analytical technology scheme for quality by design in pharmaceutical products (Saerens et al, 2014)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.